



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PDE7B siRNA (h): sc-41614

BACKGROUND

Phosphodiesterases (PDE, also designated cyclic nucleotide phosphodiesterase) are important for the downregulation of the intracellular level of the second messenger cyclic adenosine monophosphate (cAMP) by hydrolyzing cAMP to 5'AMP. Phosphodiesterase type 3 isoforms, PDE3A and 3B, are expressed primarily in cardiovascular tissue and adipose tissue, respectively. PDE3A, is found in myocardium and platelets and PDE3B is found in lymphocytes. The PDE7A1 (HCP1) isozyme and the PDE7A2 proteins, alternate splice products of PDE7A, are highly expressed in skeletal muscle. PDE7B is most highly expressed in pancreas. The PDE family contains proteins that serve tissue-specific roles in regulation of lipolysis, glycogenolysis, myocardial contractility, and smooth muscle relaxation.

REFERENCES

- Bloom, T.J. and Beavo, J.A. 1996. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. *Proc. Natl. Acad. Sci. USA* 93: 14188-14192.
- Han, P., Zhu, X. and Michaeli, T. 1997. Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. *J. Biol. Chem.* 272: 16152-16157.
- Sheth, S.B., Chaganti, K., Bastepe, M., Ajuria, J., Brennan, K., Biradavolu, R. and Colman, R.W. 1997. Cyclic AMP phosphodiesterases in human lymphocytes. *Br. J. Haematol.* 99: 784-789.
- Fisher, D.A., Smith, J.F., Pillar, J.S., St. Denis, S.H. and Cheng, J.B. 1998. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. *Biochem. Biophys. Res. Commun.* 246: 570-577.
- Gantner, F., Gotz, C., Gekeler, V., Schudt, C., Wendel, A. and Hatzelmann, A. 1998. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. *Br. J. Pharmacol.* 123: 1031-1038.
- Cheung, P.P., Yu, L., Zhang, H. and Colman, R.W. 1998. Partial characterization of the active site human platelet cAMP phosphodiesterase, PDE3A, by site-directed mutagenesis. *Arch. Biochem. Biophys.* 360: 99-104.
- Liu, H. and Maurice, D.H. 1998. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. *Br. J. Pharmacol.* 125: 1501-1510.
- Kasuya, J., Liang, S.J., Goko, H., Park, S.H., Kato, K., Xu, Z.D., Hockman, S., Manganiello, V.C. and Fujita-Yamaguchi, Y. 2000. Cardiac type cGMP-inhibited phosphodiesterase (PDE3A) gene structure: similarity and difference to adipocyte type PDE3B gene. *Biochem. Biophys. Res. Commun.* 268: 827-834.
- Hetman, J.M., Soderling, S.H., Glavas, N.A. and Beavo, J.A. 2000. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. *Proc. Natl. Acad. Sci. USA* 97: 472-476.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

CHROMOSOMAL LOCATION

Genetic locus: PDE7B (human) mapping to 6q23.3.

PRODUCT

PDE7B siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see PDE7B shRNA Plasmid (h): sc-41614-SH and PDE7B shRNA (h) Lentiviral Particles: sc-41614-V as alternate gene silencing products.

For independent verification of PDE7B (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-41614A, sc-41614B and sc-41614C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

PDE7B siRNA (h) is recommended for the inhibition of PDE7B expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor PDE7B gene expression knockdown using RT-PCR Primer: PDE7B (h)-PR: sc-41614-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.